Inventaire - your friends and communities are your best library

New onset diabetes after nivolumab treatment.

published in: BMJ case reports

date of publication: 2018-01-29

Cites articles 21

Date

Title

Authors

2017-04-01

A case of fulminant type 1 diabetes mellitus, with a precipitous decrease in pancreatic volume, induced by nivolumab for malignant melanoma: analysis of HLA and CTLA-4 polymorphisms
2017-06-13

Aggravation of diabetes, and incompletely deficient insulin secretion in a case with type 1 diabetes-resistant human leukocyte antigen DRB1*15:02 treated with nivolumab

Kimio Matsumura, Yoichi Oshima, Hironori Uruga
2017-05-16

Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer
2017-06-20

Autoimmune diabetes induced by PD-1 inhibitor-retrospective analysis and pathogenesis: a case report and literature review
2016-04-11

A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome
2016-04-13

Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy

Lars Hofmann, Jochen Utikal, Ioannis Thomas, Claus Garbe, Thomas Kurt Eigentler, Reinhard Dummer
2016-04-18

Fulminant type 1 diabetes mellitus with anti-programmed cell death-1 therapy
2016-01-01

Nivolumab, an Anti-Programmed Cell Death-1 Antibody, Induces Fulminant Type 1 Diabetes
2016-06-23

Case of type 1 diabetes associated with less-dose nivolumab therapy in a melanoma patient

Mitsuhiko Noda
2016-10-01

Fulminant type I diabetes mellitus associated with nivolumab in a patient with relapsed classical Hodgkin lymphoma

Wataru Munakata
2016-10-19

A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes

Francis Giles
2016-11-23

Glucocorticoids did not reverse type 1 diabetes mellitus secondary to pembrolizumab in a patient with metastatic melanoma

Grant McArthur, Peter Lau
2016-12-23

Association of Serum Anti-GAD Antibody and HLA Haplotypes with Type 1 Diabetes Mellitus Triggered by Nivolumab in Patients with Non-Small Cell Lung Cancer

Shingo Matsumoto, Kiyotaka Yoh, Koichi Goto
2016-12-20

Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy

Brent A Hanks
2015-06-01

Low programmed cell death-1 (PD-1) expression in peripheral CD4(+) T cells in Japanese patients with autoimmune type 1 diabetes.
2015-04-01

Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy

Mario Sznol, Scott Gettinger, Kevan C Herold
2015-04-01

Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report

Sergio A Quezada
2015-06-26

Anti-PD-1 and Anti-PDL-1 Monoclonal Antibodies Causing Type 1 Diabetes

Jerry P. Palmer, Barbara M Brooks-Worrell
2015-08-26

Anti-PD1 Pembrolizumab Can Induce Exceptional Fulminant Type 1 Diabetes

Jean-Jacques Grob
2014-07-01

Nivolumab: a review of its use in patients with malignant melanoma

Emma D Deeks
2009-07-01

Hyperglycemic crises in adult patients with diabetes

Abbas E Kitabchi

Article - wd:Q47645007

Welcome to Inventaire

the library of your friends and communities

learn more